RxDoctor Payments Data

Deeanne Seeger

Family · Pittsburgh, PANPI 1447517917

Payments from drug & device makers

$6,229in general payments, 2019–2025

Across 78 payments — averaging $79.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biosense Webster, Inc.$4K
  • Johnson & Johnson$614
  • Medtronic$579
  • Impulse Dynamics (USA) Inc.$498
  • E.r. Squibb & Sons, L.L.C.$217
  • Boston Scientific$191
  • plus $556 from 6 others

What the payments were for

  • Consulting fees$2,25136%
  • Travel & lodging$2574%
  • Food & beverage$3,72260%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,229 in reported general payments places this provider in the 95th percentile of 4,717 family providers in Pennsylvania.

See all family providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$20,554
Medicare patients
160
Services billed
224

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban320$296,459
XareltoRivaroxaban145$150,787
Dofetilide150$31,095
MultaqDronedarone Hcl15$19,034
Flecainide Acetate166$8,170
Dabigatran EtexilateDabigatran Etexilate Mesylate19$6,479
Mexiletine Hcl57$3,365
Diltiazem 24hr Er (Cd)Diltiazem Hcl187$3,166
Metoprolol Succinate154$2,048
SotalolSotalol Hcl70$1,990
Amiodarone Hcl125$1,868
Metoprolol Tartrate43$260
Cartia XtDiltiazem Hcl11$244
Carvedilol53$216
Diltiazem 12hr ErDiltiazem Hcl14$200

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$153$296,459320 claims
Johnson & JohnsonXarelto$614$150,787145 claims
Sanofi-aventis U.S. LLCMultaq$38$19,03415 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,717 family providers in Pennsylvania.

Other family in Pittsburgh

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →